NASDAQ:LTRN Lantern Pharma Q1 2026 Earnings Report $2.80 +0.20 (+7.47%) As of 02:34 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lantern Pharma EPS ResultsActual EPS-$0.30Consensus EPS -$0.36Beat/MissBeat by +$0.06One Year Ago EPSN/ALantern Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALantern Pharma Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time4:00PM ETUpcoming EarningsLantern Pharma's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lantern Pharma Earnings HeadlinesLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...August 4 at 8:45 AM | finance.yahoo.comLantern Pharma Spins Off Open-Medicine AI PlatformAugust 3 at 6:30 PM | tipranks.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 4 at 1:00 AM | Investors Alley (Ad)Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineAugust 3 at 7:30 AM | businesswire.comLantern Pharma (NASDAQ:LTRN) Shares Down 3.5% - Here's WhyJuly 30, 2026 | americanbankingnews.comLantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder CancerJuly 28, 2026 | businesswire.comSee More Lantern Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email. Email Address About Lantern PharmaLantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment. The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies. Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.View Lantern Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
